Skip to content
HALOPERIDOL Injection, USP Print E-mail
Haloperidol
 
LATEX-FREE • AP RATED
 
Innovator Product Name:HALDOL® (HALDOL is a registered trademark of Johnson & Johnson Corporation)  Electronic Catalog
Therapeutic Category: Antipsychotic

  • Consider these SAGENT Benefits:
  • • Available in
  •   - 5 mg per mL single-dose vials*
      - 50 mg per 10 mL multi-dose vials
  • • LATEX-FREE
  • • Discover PreventIV MeasuresSM packaging features:
  •   - Easy-to-read drug name and dosage strength to aid in identifying the right product
  •   - Bar codes included on the vial and carton for ease of scanning
  •   - Unique label design to help products stand out on the shelf
  • • Enhanced packaging and labeling designed to promote safety and help reduce medication errors
NDC #25021
 Description Strength Fill Volume Concentration
 Container Size Closure Unit of Sale
 Package Insert Storage Requirements Product Photos 360o View
806-01 Amber Glass Vial 5 mg 1 mL
 5 mg per mL
 2 mL 13 mm 10 Package Insert Package Insert
 Product Photos 360 Product View
823-10 Amber Glass Vial 50 mg 10 mL
 5 mg per mL
 10 mL 13 mm
 1 Package Insert Package Insert
 Product Photos 360 Product View
  * Preservative-free
Haloperidol Catalog Insert    MSDS Sheet    Bar Codes    Wholesaler Item Numbers
WARNING:
Increased Mortality in Elderly Patients with Dementia-Related Psychosis
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Haloperidol injection is not approved for the treatment of patients with dementia-related psychosis (see WARNINGS).
   Please refer to full prescribing information.

 [Back to Products page]
LATEX-FREE = There is no natural rubber latex in the vial container closure or label adhesive in this SAGENT product.
This product information is intended for U.S. residents only.  All trademarks and registered trademarks are the property of their respective owners.